Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pharmacogenetics and pharmacogenomics].

Michel Bourel1, Raymond Ardaillou

  • 1l'Académie Nationale de Médecine.

Bulletin De L'Academie Nationale De Medecine
|August 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Reforming Biosciences and Health Research: Part I, Funding].

Bulletin de l'Academie nationale de medecine·2021
Same author

The history of renal transplantation in France.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2018
Same author

Medecine sciences : M/S·2016
Same author

Gabriel Richet: the Man and the Scientist.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2016
Same author

Gabriel Richet (1916-2014).

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2014
Same author

[Transgenic mice: a major advance in biomedical research].

Bulletin de l'Academie nationale de medecine·2010

Genetic variations impact drug response, causing adverse effects due to altered enzyme function. Understanding these genetic polymorphisms is crucial for personalized medicine and safer drug prescriptions.

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Clinical Genetics

Background:

  • Genetic polymorphisms in drug-metabolizing enzymes (e.g., cytochrome P450s) can alter drug efficacy and safety.
  • Phase I and Phase II enzymes play critical roles in drug metabolism, with variations impacting drug clearance and metabolite levels.
  • Common polymorphisms in CYP2D6 and CYP2C9 significantly influence the metabolism of numerous medications.

Discussion:

  • Altered enzyme activity due to genetic variants can lead to suboptimal drug dosing, potentially causing overdose or underdosing.
  • Specific gene mutations, such as those in thiopurine methyltransferase or UDP-glucuronyltransferase, increase the risk of severe adverse events like bone marrow aplasia.
  • Polymorphisms in target molecules, like vitamin K epoxide reductase, directly affect drug action, as seen with vitamin K antagonists.

Related Experiment Videos

Key Insights:

  • Genotyping for genetic polymorphisms should be complemented by phenotyping to confirm functional impact on drug metabolism.
  • Somatic mutations in tumors can influence patient response to anticancer therapies, necessitating tailored treatment strategies.
  • Identifying genetic predispositions to adverse drug reactions is essential for optimizing therapeutic outcomes.

Outlook:

  • Genomic analysis for frequent polymorphisms in patients prescribed high-risk drugs is recommended for improved safety.
  • Collecting DNA from clinical trials will facilitate research into the relationship between gene polymorphisms and adverse drug events.
  • Establishing biological resource centers in hospitals will support the storage and analysis of tissue specimens for pharmacogenomic studies.